Guggenheim Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $25
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and raises the price target from $20 to $25.
Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and raises the price target from $20 to $25.